149 related articles for article (PubMed ID: 3525770)
1. A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer.
Brown TD; Ettinger DS; Donehower RC
J Clin Oncol; 1986 Aug; 4(8):1270-6. PubMed ID: 3525770
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of spiromustine (NSC 172112) and evaluation of toxicity and schedule in a murine model.
Pazdur R; Redman BG; Corbett T; Phillips M; Baker LH
Cancer Res; 1987 Aug; 47(15):4213-7. PubMed ID: 3607760
[TBL] [Abstract][Full Text] [Related]
3. A pediatric phase I and pharmacokinetic study of spirohydantoin mustard.
Heideman RL; Kelley JA; Packer RJ; Reaman GH; Roth JS; Balis F; Ettinger LJ; Doherty KM; Jeffries SL; Poplack DG
Cancer Res; 1988 Apr; 48(8):2292-5. PubMed ID: 3349492
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of spirogermanium given daily.
Legha SS; Ajani JA; Bodey GP
J Clin Oncol; 1983 May; 1(5):331-6. PubMed ID: 6668504
[TBL] [Abstract][Full Text] [Related]
5. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
6. Spiromustine: a new agent entering clinical trials.
Shoemaker DD; O'Dwyer PJ; Marsoni S; Plowman J; Davignon JP; Davis RD
Invest New Drugs; 1983; 1(4):303-8. PubMed ID: 6381379
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of spirohydantoin mustard for the treatment of recurrent malignant gliomas.
Prados M; Rodriguez L; Seager M; Silver P; Levin V
Cancer Treat Rep; 1987 Nov; 71(11):1105-6. PubMed ID: 3119204
[No Abstract] [Full Text] [Related]
8. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
[TBL] [Abstract][Full Text] [Related]
9. Spiromustine and intracarotid artery cisplatin in the treatment of glioblastoma multiforme.
Resio MJ; DeVroom HL
J Neurosci Nurs; 1986 Feb; 18(1):13-22. PubMed ID: 3005442
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Eckhardt SG; Baker SD; Britten CD; Hidalgo M; Siu L; Hammond LA; Villalona-Calero MA; Felton S; Drengler R; Kuhn JG; Clark GM; Smith SL; MacDonald JR; Smith C; Moczygemba J; Weitman S; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2000 Dec; 18(24):4086-97. PubMed ID: 11118470
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken JB
Anticancer Drugs; 2007 Jun; 18(5):587-95. PubMed ID: 17414628
[TBL] [Abstract][Full Text] [Related]
12. Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours.
Schöffski P; Hagedorn T; Grünwald V; Paul H; Merkle K; Kowalski R; Ganser A
J Cancer Res Clin Oncol; 2000 Jan; 126(1):41-7. PubMed ID: 10641748
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of mitozolomide.
Newlands ES; Blackledge G; Slack JA; Goddard C; Brindley CJ; Holden L; Stevens MF
Cancer Treat Rep; 1985; 69(7-8):801-5. PubMed ID: 4016790
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of menogaril in patients with advanced cancer.
Brown TD; Donehower RC; Grochow LB; Rice AP; Ettinger DS
J Clin Oncol; 1987 Jan; 5(1):92-9. PubMed ID: 2949065
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
[TBL] [Abstract][Full Text] [Related]
16. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
Hidalgo M; Rodriguez G; Kuhn JG; Brown T; Weiss G; MacGovren JP; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Nov; 4(11):2763-70. PubMed ID: 9829740
[TBL] [Abstract][Full Text] [Related]
17. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
18. Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours.
Schöffski P; Seeland G; Engel H; Grünwald V; Paul H; Merkle K; Kowalski R; Ganser A
Ann Oncol; 2000 Jun; 11(6):729-34. PubMed ID: 10942063
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
